Delaware's Supreme Court clarifies the limits of earnout protections: specific milestone language controls, efforts clauses carry real obligations.

In Fortis Advisors v. Johnson & Johnson (Jan. 12, 2026), J&J acquired a robotics company for $3.4B cash plus up to $2.35B in milestone-based earnouts. None were ever paid. The Court awarded over $600M in damages. Here's why it matters:

𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆 𝟭: 𝗪𝗿𝗶𝘁𝗲 𝗲𝘅𝗮𝗰𝘁𝗹𝘆 𝘄𝗵𝗮𝘁 𝘆𝗼𝘂 𝗺𝗲𝗮𝗻 — 𝗰𝗼𝘂𝗿𝘁𝘀 𝘄𝗼𝗻'𝘁 𝗳𝗶𝘅 𝗶𝘁 𝗹𝗮𝘁𝗲𝗿.
The milestones required a specific type of FDA clearance (510(k)). When the FDA closed that pathway, the seller argued the buyer should pursue an alternative route. The Court said no — you picked your trigger, and the contract won't be rewritten because circumstances changed. If a risk is foreseeable, even if unlikely, you must draft for it at the negotiating table.

𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆 𝟮: "𝗥𝗲𝗮𝘀𝗼𝗻𝗮𝗯𝗹𝗲 𝗲𝗳𝗳𝗼𝗿𝘁𝘀" 𝗰𝗹𝗮𝘂𝘀𝗲𝘀 𝗮𝗿𝗲𝗻'𝘁 𝗲𝗺𝗽𝘁𝘆 𝗽𝗿𝗼𝗺𝗶𝘀𝗲𝘀.
J&J committed to pursue the milestones with the same effort it gave its own top-priority products. Instead, it ran an internal competition that set the acquired product back, merged it with a rival platform, and stripped employee incentives tied to the milestones. The Court held that a buyer can choose how to pursue a milestone, but it cannot abandon the goal altogether while hiding behind business judgment.

𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆 𝟯: 𝗟𝘆𝗶𝗻𝗴 𝗱𝘂𝗿𝗶𝗻𝗴 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗼𝗻𝘀 𝗰𝗮𝗻 𝗰𝗼𝘀𝘁 𝘆𝗼𝘂 — 𝗲𝘃𝗲𝗻 𝗮𝗳𝘁𝗲𝗿 𝗰𝗹𝗼𝘀𝗶𝗻𝗴.
J&J's CEO pitched a $100M milestone as a near-certainty while concealing a patient death and FDA investigation that threatened it. The contract's exclusive remedy clause didn't save J&J because only J&J — not the seller — had agreed not to rely on statements made outside the contract. If you want protection from fraud claims based on what was said at the negotiating table, both sides must expressly disclaim reliance.

Fortis v. J&J is now the leading Delaware earnout opinion — addressing milestone drafting precision, the enforceability of efforts obligations, and the limits of exclusive remedy clauses against extra-contractual fraud. Essential reading for anyone structuring contingent consideration.Court: Delaware Supreme Court
Date: January 2026 — Fortis Advisors v. Johnson & Johnson

Summary of Relevant Facts

Johnson & Johnson acquired a medical device company in a $3.4 billion deal that included up to $2.35 billion in milestone-based earnout payments contingent on achieving specified regulatory and commercial objectives. The acquisition agreement required J&J to pursue FDA 510(k) clearance for the acquired product and to devote reasonable efforts — equivalent to those given to its top-tier products — toward achieving the earnout milestones. After the acquisition, the FDA 510(k) pathway specified in the contract became unavailable. J&J did not pursue alternative regulatory pathways. Internally, J&J created competing products, merged development platforms, and eliminated incentive structures for employees working on the earnout milestones. None of the $2.35 billion in earnout payments were ever made. Additionally, the seller's CEO had represented during pre-closing negotiations that a $100 million milestone was nearly certain, while concealing a patient death and an ongoing FDA investigation related to the product.

Procedural Background

Fortis Advisors, acting as the representative of the former shareholders of the acquired company, filed suit in Delaware alleging breach of the earnout provisions and fraud. The case was tried and ultimately reached the Delaware Supreme Court. The court awarded over $600 million in damages.

Main Controversies

The case presented three central issues:

1. Whether the buyer was obligated to pursue alternative regulatory pathways when the specific pathway (FDA 510(k) clearance) identified in the contract became unavailable.

2. Whether the buyer's internal actions — creating competing products, merging platforms, and eliminating employee incentives — constituted a breach of its "reasonable efforts" obligations under the earnout provisions.

3. Whether the seller's pre-closing fraud regarding the near-certainty of a milestone (while concealing adverse safety information) was barred by the contract's exclusive remedy clause.

Position of the Parties

Fortis Advisors (Seller Representative/Plaintiff): Argued that J&J breached its obligation to use reasonable efforts by internally sabotaging the product's development — creating competing products, eliminating employee incentives, and merging platforms. Fortis also alleged that J&J's failure to pursue any alternative regulatory pathway demonstrated bad faith. On the fraud claim, Fortis argued that the CEO's concealment of the patient death and FDA investigation constituted actionable fraud not barred by the exclusive remedy clause.

Johnson & Johnson (Buyer/Defendant): Argued that the contract specifically identified the FDA 510(k) pathway, and when that pathway became unavailable, J&J had no obligation to pursue alternatives. J&J contended that its internal business decisions were protected exercises of business judgment. On the fraud claim, J&J argued that the exclusive remedy clause barred all claims arising from pre-closing representations.

Holding

The Delaware Supreme Court ruled largely in favor of Fortis Advisors, awarding over $600 million in damages. The court held that: (1) precise milestone language controlled, and the buyer was not required to pursue alternative pathways; (2) however, the buyer's "reasonable efforts" obligations carried real, enforceable content, and the buyer breached those obligations by abandoning pursuit of the milestones; and (3) the exclusive remedy clause did not bar the fraud claim because the anti-reliance provision was one-sided.

Reasons for the Decision

On milestone specificity, the court held that the contract's identification of the FDA 510(k) pathway was precise and controlling. When that specific regulatory route became unavailable, the buyer could not be compelled to pursue alternative pathways not contemplated by the agreement. Courts will not rewrite agreements because circumstances changed.

On the reasonable efforts clause, the court drew a critical distinction between choosing how to pursue earnout goals and abandoning them entirely. J&J's actions — creating internal competition, merging the acquired product's development platform, and eliminating incentive structures — constituted abandonment rather than a legitimate exercise of business judgment. J&J had promised to treat the acquired product with priority equivalent to its top-tier products, and its conduct fell far short.

On the fraud and exclusive remedy question, the court held that exclusive remedy clauses protect against fraud claims only when both parties have disclaimed reliance on extra-contractual statements. Here, only the seller had made a non-reliance representation — the buyer had not. Because the anti-reliance provision was one-sided, the exclusive remedy clause did not bar Fortis's fraud claim.

This case summary is provided for educational and informational purposes only. It should not be construed as legal advice.